Boston:Researchers at Banner Health, Lund University in Sweden, and other international collaborators have developed the first scalable blood test capable of measuring a protein fragment known as eMTBR-tau. This fragment is crucial for tracking the buildup of tau tangles, a key indicator of Alzheimer's disease.
According to Emirates News Agency, the study, published in the Journal of the American Medical Association (JAMA), reveals that the new blood test accurately detects advanced tau pathology. It demonstrates clearer distinctions between early and late-stage Alzheimer's disease compared to p-tau217, the current widely used blood marker in Alzheimer's research and clinical care. While p-tau217 tracks the buildup of amyloid plaques early in the disease process, it provides limited information about tau tangle buildup in later stages.
The new test focuses on a different biological signal that more directly tracks the spread of tau tangles through the brain. This suggests that the two markers could work together to offer a more comprehensive understanding of disease progression. Professor Niklas Mattsson-Carlgren, MD, PhD, of Lund University, emphasized the importance of the test for diagnosing advanced Alzheimer's pathology in patients with cognitive impairment.
Nicholas Ashton, PhD, senior director of Banner's Fluid Biomarker Programme, highlighted that this development represents a significant advancement in understanding Alzheimer's disease. The test, which requires only a minimal blood sample, can now be conducted at scale, potentially becoming a routine part of clinical care and research.
